The Journal of Thoracic and Cardiovascular Surgery
Volume 128, Issue 4 , Pages 588-594 , October 2004

FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury

  • Masaki Yada, MD

      Affiliations

    • Department of Thoracic & Cardiovascular Surgery, Mie University School of Medicine, Tsu, Japan
    • ,
  • Akira Shimamoto, MD, PhD

      Affiliations

    • Department of Thoracic & Cardiovascular Surgery, Mie University School of Medicine, Tsu, Japan
    • Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash, USA
    • Corresponding Author InformationAddress for reprints: Akira Shimamoto, MD, PhD, Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, 1959 NE Pacific St, Box 356310, Seattle, WA 98195-6310, USA
    • ,
  • Craig R. Hampton, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash, USA
    • ,
  • Albert J. Chong, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash, USA
    • ,
  • Hiroo Takayama, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash, USA
    • ,
  • Christine L. Rothnie, BS

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash, USA
    • ,
  • Denise J. Spring, PhD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash, USA
    • ,
  • Hideto Shimpo, MD, PhD

      Affiliations

    • Department of Thoracic & Cardiovascular Surgery, Mie University School of Medicine, Tsu, Japan
    • ,
  • Isao Yada, MD, PhD

      Affiliations

    • Department of Thoracic & Cardiovascular Surgery, Mie University School of Medicine, Tsu, Japan
    • ,
  • Timothy H. Pohlman, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash, USA
    • ,
  • Edward D. Verrier, MD

      Affiliations

    • Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash, USA

Received 21 October 2003 ,Revised 16 January 2004 ,Accepted 2 February 2004.

References 

  1. Verma S, Fedak PW, Weisel RD, Butany J, Rao V, Maitland A, et al.  Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002;105:2332–2336
  2. Weisel RD. Myocardial stunning after coronary bypass surgery. J Card Surg. 1993;8:242–244
  3. Meyers BF, Lynch J, Trulock EP, Guthrie TJ, Cooper JD, Patterson GA. Lung transplantation (a decade of experience). Ann Surg. 1999;230:362–371
  4. Verrier ED, Morgan EN. Endothelial response to cardiopulmonary bypass surgery. Ann Thorac Surg. 1998;66:S17–19
  5. Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, et al.  Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion. Circ Res. 1996;79:162–173
  6. Knight RJ, Buxton DB. Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart. Biochem Biophys Res Commun. 1996;218:83–88
  7. Ma XL, Kumar S, Gao F, Louden CS, Lopez BL, Christopher TA, et al.  Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 1999;99:1685–1691
  8. Mackay K, Mochly-Rosen D. An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia. J Biol Chem. 1999;274:6272–6279
  9. Hreniuk D, Garay M, Gaarde W, Monia BP, McKay RA, Cioffi CL. Inhibition of c-Jun N-terminal kinase 1, but not c-Jun N-terminal kinase 2, suppresses apoptosis induced by ischemia/reoxygenation in rat cardiac myocytes. Mol Pharmacol. 2001;59:867–874
  10. Martin JL, Avkiran M, Quinlan RA, Cohen P, Marber MS. Antiischemic effects of SB203580 are mediated through the inhibition of p38α mitogen-activated protein kinase (evidence from ectopic expression of an inhibition-resistant kinase). Circ Res. 2001;89:750–752
  11. Fan H, Sun B, Gu Q, Lafond-Walker A, Cao S, Becker LC. Oxygen radicals trigger activation of NF-κB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol. 2002;282:H1778–1786
  12. Lakshminarayanan V, Lewallen M, Frangogiannis NG, Evans AJ, Wedin KE, Michael LH, et al.  Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol. 2001;159:1301–1311
  13. Nossuli TO, Frangogiannis NG, Knuefermann P, Lakshminarayanan V, Dewald O, Evans AJ, et al.  Brief murine myocardial ischemia-reperfusion induces chemokines in a TNF-α–independent manner (role of oxygen radicals). Am J Physiol Heart Circ Physiol. 2001;281:H2549–2558
  14. Kacimi R, Karliner JS, Koudssi F, Long CS. Expression and regulation of adhesion molecules in cardiac cells by cytokines (response to acute hypoxia). Circ Res. 1998;82:576–586
  15. Takahashi S, Keto Y, Fujita T, Uchiyama T, Yamamoto A. FR167653, a p38 mitogen-activated protein kinase inhibitor, prevents Helicobacter pylori–induced gastritis in Mongolian gerbils. J Pharmacol Exp Ther. 2001;296:48–56
  16. Hampton CR, Shimamoto A, Rothnie CL, Griscavage-Ennis J, Chong A, Dix DJ, et al.  HSP70.1 and -70.3 are required for late-phase protection induced by ischemic preconditioning of mouse hearts. Am J Physiol Heart Circ Physiol. 2003;285:H866–874
  17. Nakano A, Cohen MV, Critz S, Downey JM. SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Basic Res Cardiol. 2000;95:466–471
  18. Mocanu MM, Baxter GF, Yue Y, Critz SD, Yellon DM. The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. Basic Res Cardiol. 2000;95:472–478
  19. Maulik N, Yoshida T, Zu YL, Sato M, Banerjee A, Das DK. Ischemic preconditioning triggers tyrosine kinase signaling (a potential role for MAPKAP kinase 2). Am J Physiol. 1998;275(5 Pt 2):H1857–1864
  20. Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem. 1998;273:28766–28772
  21. Clerk A, Sugden PH. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett. 1998;426:93–96
  22. Sugden PH, Clerk A. “Stress-responsive” mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res. 1998;83:345–352
  23. Wang Y, Huang S, Sah VP, Ross J, Brown JH, Han J, et al.  Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273:2161–2168
  24. Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA, Lochner A. Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. J Mol Cell Cardiol. 2001;33:769–778
  25. Barancik M, Htun P, Strohm C, Kilian S, Schaper W. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death. J Cardiovasc Pharmacol. 2000;35:474–483
  26. Saurin AT, Martin JL, Heads RJ, Foley C, Mockridge JW, Wright MJ, et al.  The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes. FASEB J. 2000;14:2237–2246
  27. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38α in erythropoietin expression (a role for stress kinases in erythropoiesis). Cell. 2000;102:221–231
  28. Otsu K, Yamashita N, Nishida K, Hirotani S, Yamaguchi O, Watanabe T, et al.  Disruption of a single copy of the p38α MAP kinase gene leads to cardioprotection against ischemia-reperfusion. Biochem Biophys Res Commun. 2003;302:56–60
  29. Gao F, Yue TL, Shi DW, Christopher TA, Lopez BL, Ohlstein EH, et al.  p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovasc Res. 2002;53:414–422
  30. Morgan EN, Boyle EM, Yun W, Griscavage-Ennis JM, Farr AL, Canty TG, et al.  An essential role for NF-κB in the cardioadaptive response to ischemia. Ann Thorac Surg. 1999;68:377–382
  31. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739–746
  32. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000;47:185–201
  33. Ravingerova T, Barancik M, Strniskova M. Mitogen-activated protein kinases (a new therapeutic target in cardiac pathology). Mol Cell Biochem. 2003;247:127–138

☆ Supported in part by the National Institutes of Health grant 5R01HL061762 and a Grant-in-Aid for Scientific Research (No. 14370408) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

PII: S0022-5223(04)00261-2

doi: 10.1016/j.jtcvs.2004.02.007

The Journal of Thoracic and Cardiovascular Surgery
Volume 128, Issue 4 , Pages 588-594 , October 2004

Article Tools

* Image Usage & Resolution